The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools…
NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung…
Program Augments Existing Patient Advocacy and Professional Society Donationsto Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is September…
Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential…
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today…
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in…
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE…
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a…
BOULDER, Colo., July 30, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”), a leading diagnostics company specializing in the development…
CDC reports burden of six hard-to-treat superbugs increased by a combined 20% in 2021 and 2022 compared with 2019CDC call…